Industry

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–$EOLS–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference. Event: H.C. Wainwright 24th Annual Global Investment Conference Date: Monday, September 12, 2022 Time: Available … [Read more…]

VANCOUVER, British Columbia–(BUSINESS WIRE)–#education–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO), a Veteran and Nurse lead ketamine wellness company, is pleased to report updated company structures aligning the mission of the company for aggressive strategic growth opportunities in the psychedelic wellness field. Revitalist CEO, Kathryn Walker states, “Revitalist … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Molecular Biology Enzymes, Kits, and Reagents Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product, Application, and End User” report has been added to ResearchAndMarkets.com’s offering. The molecular biology enzymes, kits, and reagents market was valued at US$ 10,987.17 million in 2020 and it is projected to reach US$ 41,104.71 … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Inhalation & Nasal Sprays Generic Drugs Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Inhalation & Nasal Sprays Generic Drugs Market is projected to reach USD 11,272.80 million by 2027 from USD 6,883.36 million in 2021, at a CAGR 8.56% during the forecast period. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global HIV Vaccines Market (2022-2027) by Type, Antibodies, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. The Global HIV Vaccines Market is estimated to be USD 479.61 Mn in 2022 and is expected to reach USD 616.8 Mn by 2027, growing at a … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Africa Immuno-oncology Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2028” report has been added to ResearchAndMarkets.com’s offering. The regional research report on Africa immuno-oncology market is a customer intelligence and competitive study of the Africa market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and … [Read more…]

Analyses of contemporary data from the European SANTORINI registry highlight the need to address the ongoing discrepancy between guideline recommendations and clinical practice when it comes to the perception of risk for cardiovascular disease (CVD) in patients.1,2 Data on lipid lowering and CV risk profile in 14 countries show that the underutilisation of combination therapy … [Read more…]

DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced it submitted a planning application to expand its development and manufacturing facility in Waterford, Ireland to add new drug substance biologics development and manufacturing capabilities. The planned facility would expand Horizon’s footprint, adding approximately 320,000 square feet to its current 44,000 square foot drug product (fill-finish) biologics … [Read more…]

First in-vivo data for ONKT102, a fully human, optimized affinity CD38 CAR-NK cell therapy Data showed potent anti-tumor activity in-vitro and in-vivo of cord-derived ONKT102 in a CD38 positive tumor model of multiple myeloma Poster presented at the International Myeloma Society 2022, 25-27 August 2022, Los Angeles, USA by CSO Prof. Michael O’Dwyer GALWAY, Ireland … [Read more…]

Teva Pharmaceuticals to commercialize the product in Europe Age related macular degeneration (AMD) affects around 67 million people in Europe and is a leading cause of blindness for working age adults with uncontrolled diabetes1 and the most common cause of blindness in developed countries2. Ranivisio (ranibizumab) will be the first ophthalmology biosimilar of Lucentis to … [Read more…]